Mycophenolic Acid 180mg Delayed-Release Tablets

Mycophenolic Acid 180mg is a delayed-release mycophenolic-acid immunosuppressant used as part of a kidney-transplant anti-rejection regimen. Its enteric coating delays release until the medicine reaches the intestine.
Take delayed-release tablets consistently on an empty stomach, one hour before or two hours after a meal. Swallow whole without crushing, splitting or chewing the enteric coating.
Mycophenolic acid inhibits IMP dehydrogenase, reducing guanine-nucleotide synthesis needed for multiplication of activated T and B lymphocytes.
Diarrhoea, vomiting, abdominal discomfort and reduced white-cell counts are common concerns; infections can occur more readily.
Exposure during pregnancy can cause miscarriage and severe birth defects. Pregnancy testing, effective contraception, blood counts and infection surveillance are essential parts of treatment. Women who can become pregnant require effective contraception during treatment and for six weeks after stopping; the transplant team plans any pregnancy-related change before treatment is interrupted.
Helps prevent kidney-transplant rejection when combined with the other anti-rejection medicines in the transplant regimen, supporting continued function of the transplanted kidney.
No. Different formulations have different strengths and absorption characteristics; the transplant team must manage a switch.
Contact the transplant team; dehydration, infection and altered medicine exposure need assessment.
No. Keep the enteric-coated tablet intact. If swallowing is difficult, the transplant team can arrange a suitable alternative; do not crush it or expose anyone to damaged medicine.
Treatment can suppress white cells and other blood cells, increasing infection or bleeding risk.
Magnesium- or aluminium-containing antacids can reduce absorption; obtain a separation schedule.
It requires advance specialist planning and an alternative regimen where appropriate; do not stop anti-rejection treatment yourself.
No. Rejection prevention remains necessary even without symptoms.
They are generally avoided during immunosuppressive treatment, and vaccine responses may be reduced.
Enteric coating: a coating that delays release until the intestine. Lymphocyte: an immune cell involved in rejection. Mycophenolic acid: the active immunosuppressive compound.; AR: Mycophenolic Acid 180mg أقراص متأخرة التحرر; FR: Mycophenolic Acid 180mg comprimés à libération retardée; PT: Mycophenolic Acid 180mg comprimidos de libertação retardada; ES: Mycophenolic Acid 180mg comprimidos de liberación retardada; RU: Mycophenolic Acid 180mg таблетки с отсроченным высвобождением; ID: Mycophenolic Acid 180mg tablet lepas tunda; VI: Mycophenolic Acid 180mg viên nén giải phóng chậm; MS: Mycophenolic Acid 180mg tablet pelepasan tertunda; TL: Mycophenolic Acid 180mg tabletang may naantalang paglabas; ZH-SG: Mycophenolic Acid 180mg 迟释片
International B2B Enquiry
Send a structured B2B enquiry for Mycophenolic Acid 180mg Delayed-Release Tablets under Transplant Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Mycophenolic Acid 180mg Delayed-Release Tablets